At 10 a.m. on June 6, 2022, Huanyu Biotech held a grand press conference at the Jiangzhou International Conference Center.

In the past year or so, Uniworld has held a press conference every three or five days, and each time it is a major breakthrough in medicine or technological innovation.

Because of this, as soon as the news was released, countless reporters from home and abroad flocked to it, and thousands of reporters filled the huge press room.

Lin Wei, Vice President and Chief Information Officer of Universal Biotech, presided over the press conference.

Under the attention of countless reporters, Lin Wei said with excitement: "Good morning, all kinds of guest reporters and friends, welcome to participate in the press conference of Huanyu......"

Click!!

In the interval between Lin Wei's speeches, the press conference hall instantly became a sea of magnesium lights.

Lin Wei paused and said: "Here I want to tell you a good news, under the leadership of Zhou Wen, chief scientist of Huanyu Biotechnology, Lin Ming, senior engineer, and academician He Junfeng, deputy director and chief scientist of the Institute of Hepatitis B of the Chinese Academy of Sciences, and with the continuous efforts of hundreds of other scientific researchers, we have successfully conquered viral hepatitis B!"

There was some silence at the beginning of the press conference, but the next second, a loud buzzing sound erupted from the scene.

"What do you mean, is there a new drug?"

"I don't understand this, conquering it is healing!"

"No, the hepatitis B virus can't be cured. ”

"Then I don't know......"

Lin Wei gave the reporters on the scene more than ten seconds to digest what he had just said, and then explained their research results.

When the reporter at the scene learned that this drug will cure nearly 300 million hepatitis B virus patients around the world, a heated discussion broke out.

……

The news that the hepatitis B virus had been conquered instantly spread to countries around the world.

Countless hepatitis B patients were naturally very excited when they saw the news.

However, some more than a dozen pharmaceutical companies that are researching new hepatitis B drugs and have even gone to the clinical trial stage were struck by lightning when they heard the news.

Especially the 6 pharmaceutical companies that got the data of Huanyu Biologics' formula, they spent so much energy to do this, but they didn't expect to end up doing all of it uselessly.

……

Kyoto Inner Ring Road, inside a building where the national emblem is hung.

A man with a Chinese face was reading an internal reference news, and soon read the news.

He had a slightly surprised look on his face, and asked in a deep voice, "Is this news true?"

The confidential secretary who was sorting out the information next to him immediately said respectfully: "Yes, chief, the experts from the Food and Drug Administration have tested it with DGD technology, and it is true." ”

The man with the national character face nodded, a smile appeared on his serious face, and said with a smile: "No wonder you dare to pack tickets with me, it seems that you have been prepared for a long time!"

The confidential secretary smiled and said, "Yes! Professor Zhou's level in the field of medicine is indeed worthy of the word miracle doctor." ”

It is self-evident how important DGD technology is to pharmaceutical companies, and it can be called one of the greatest inventions in the pharmaceutical industry.

The same is true for European and American countries, and the technology of European and American companies cannot be exported to China casually.

So you can imagine how fiercely opposed Uniworld Biotech was when it proposed DGD technology sharing?

Including many upper-level bigwigs who trust Zhou Wen very much, they also oppose it.

However, Zhou Wen still persuaded a group of bigwigs.

Zhou Wen's reason is very good, DGD technology is important, but if you want to regain the standard of the global pharmaceutical market, it is far from enough to rely on a DGD technology.

First of all, the NMPA has always been the first to look at the FDA, and freezing three feet is not a day's cold, and it is not a day or two to completely reverse this situation.

Because there are a lot of interests involved.

There are interests and disputes, many people are unwilling to leave their comfort zone, to explore the unknown field, do a good job is the leader, do not do well, or make a mistake, the specific manager will be unlucky, so the promotion of DGD technology in China has encountered great resistance.

Secondly and most importantly, European and American countries will definitely not allow the DGD technology mastered by Chinese companies to be implemented in their own countries, even if the academic community supports it, it is useless for pharmaceutical companies to advocate it.

Don't even think about it.

Then the problem arises, even if China's NMPA adopts the DGD technical standard, if the drug developed by Universal Biotech wants to be sold abroad, it still needs to go through the time-consuming and lengthy clinical trial procedure again.

Some people may want to say that it is their business that European and American countries are willing to be complacent, and it is a big deal to sell them domestically.

But Zhou Wen can't wait, his new drug research and development speed is far beyond the imagination of ordinary people, holding a large number of new drugs to be brought to the market, but the lengthy clinical trial time has led to the drug not being able to go on the market as quickly as cosmeceutical hair growth lottery, scar removal cream, and wrinkle removal cream.

The DGD technology is a stepping stone to the European and American pharmaceutical markets.

With the speed of Zhou Wen's drug research and development, European and American pharmaceutical companies together are not enough for him to fight.

Therefore, the DGD technology is shared with Europe and the United States, not for the convenience of European and American countries, but for the convenience of himself.

Of course, these are not known to ordinary people.

And the reason why the upper-level leaders agreed to Zhou Wen was only because of his medical skills.

Zhou Wen's medical skills have almost reached the point of being superb, and the holy hand of the national doctor is no longer enough to describe him, and the bosses and family members above now call him "divine doctor".

Can you imagine the weight of his words?

Therefore, when he patted his chest and promised the leaders that he would earn back the DGD technology with profits, the leaders finally agreed to his suggestion.

Now it seems that Zhou Wen has already prepared a killer feature!

……

……

Half a month later.

The "Qingganling Preparation" codenamed PD0079 developed by Huanyu Biotech, as well as the second-class new drugs of four or five other pharmaceutical companies, became the first batch of experimental subjects of DGD technology in China and conducted phase I clinical trials.

In the past, it took 3~6 months for a phase I clinical trial, but after using DGD technology, it only took one week to complete the trial.

Of course, "Qingganling Preparation" has successfully passed the first phase of clinical trials without surprisingly.

As soon as the news came out, it immediately caused a huge sensation.

Countless pharmaceutical laboratories and pharmaceutical companies are surprised and envious of the high efficiency and speed of DGD technology.

Relevant departments in Europe, the United States, Japan and South Korea have also accelerated the approval of DGD technology.

Soon, Hanguo became the second country to adopt DGD technology.

Japanese benzene followed.

Then there are Germany, Portugal, France, Italy, Russia......

And at such a speed like a competition, "Qingganling Preparation" has passed the second phase of clinical trials.

Everything is ready to go......